Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

KRAS

17 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma

Yousef M, Chowdhury S, Albarouki S, et al.

The oncologist

This retrospective cohort study of 1,095 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates that the pattern of metastatic spread is strongly linked to clinical outcome and genomic detection. Patients with lung-only metastases had a significantly prolonged median overall survival of 57.6 months compared to roughly 19.5 months in patients with liver-involved disease. Tissue genomic profiling identified lower TP53 mutation frequencies and higher GNAS mutation rates in non-liver and lung-only metastases. Crucially, liquid biopsy (n = 240) showed markedly lower detection rates for KRAS (10%) and TP53 (23%) in lung-only disease, underscoring that tissue-based sequencing must be prioritized in these patients to guide KRAS-directed therapeutic decisions.

Clinical · Molecular biology

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes

Hussung S, Roth M, Akhoundova D, et al.

Cancer medicine

This real-world study evaluated the implementation of upfront comprehensive genomic profiling (CGP) in 80 patients with advanced biliary tract cancer (BTC). Clinically actionable alterations were detected in 52.5% of cases—predominantly in IDH1, FGFR2, ERBB2, KRAS G12C, and BRAF—with anatomical enrichment of FGFR2 and IDH1 in intrahepatic cholangiocarcinoma. Matched targeted therapies were administered to 11 of the 42 actionable patients, yielding a significantly longer treatment duration compared with the preceding systemic line (p = 0.0391) and enabling secondary surgical resection in two patients. These findings confirm the clinical feasibility and value of upfront CGP in BTC while emphasizing the critical need to bridge the gap between biomarker identification and drug access.

Clinical · Bioinfo & AI

Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT)

Skoulidis F, Jabbour SK, Garon EB, et al.

Clinical cancer research

The TRIDENT study is a post-hoc analysis of the phase III POSEIDON trial, which evaluated the addition of tremelimumab to durvalumab and chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). This analysis utilized machine learning models integrating clinical, genomic, and radiomic data to identify patients who would derive greater overall survival (OS) benefit from the addition of tremelimumab. Results showed that the top-ranked 50% of patients with nonsquamous tumors, as identified by the model, achieved a hazard ratio of 0.56 for OS. Factors such as KRAS and STK11 mutations, along with wild-type EGFR, FGFR3, and CDKN2A, were strongly associated with higher OS benefit.

Clinical · Molecular biology

Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma

Heidrich I, Streckenbach A, Rautmann C, et al.

Journal of translational medicine

This study longitudinally analyzed circulating tumor DNA (ctDNA) in 42 patients with advanced melanoma treated with immune checkpoint inhibitors. ctDNA levels significantly correlated with radiological response according to RECIST 1.1 and total tumor volume, especially when measurements were temporally aligned. Although the discriminative performance for identifying progression was moderate, higher ctDNA thresholds demonstrated better specificity. The study also revealed marked heterogeneity in ctDNA shedding across metastatic sites, highlighting its potential as a complementary biomarker for disease monitoring.

Clinical · Molecular biology

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer

Sridalla K, Machhi JK, Vitello DJ, et al.

Clinical cancer research

This prospective study evaluated the prognostic significance of KRAS-mutant circulating tumor DNA (ctDNA) in patients with localized pancreatic ductal adenocarcinoma (PDAC). Analyses compared detection by next-generation sequencing (NGS) and digital droplet PCR (ddPCR) at various stages of perioperative treatment. Results indicated that the more sensitive ddPCR detected KRAS-mutant ctDNA in a greater proportion of patients than NGS. Detection by either method was associated with shorter overall survival, with ddPCR providing superior prognostic discrimination by identifying additional patients with poor outcomes missed by NGS. Integrating both methods could enhance perioperative risk stratification.

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical · Molecular biology

Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial

Jhaveri K, Eli LD, Hurvitz SA, et al.

Clinical cancer research

This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.

Clinical · Molecular biology

Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

Yoshikawa Y, Kubota H, Matsumoto S, et al.

Nature communications

This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.

Clinical · Molecular biology

Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer

Xie J, Wang S, Liu J, et al.

Apoptosis

This study investigates the interaction between mutated KRAS and AGO2 in colorectal cancer (CRC), a mechanism that impairs AGO2 function and promotes tumor progression. Researchers developed peptide-gold nanoparticles (Au-pep) to specifically disrupt this interaction, which restored microRNA expression, particularly let-7c-5p. This restoration led to the downregulation of key oncogenic drivers such as KRAS, c-Myc, and Bcl2, suppressing the growth of KRAS-mutated CRC cells and inducing apoptosis. Furthermore, this approach sensitized cells to existing treatments, including 5-fluorouracil and immunotherapy, by regulating ABCC5 and PD-L1.

Clinical · Molecular biology

Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine

Crane K, Bhat KRS, Grivas P, et al.

Oncotarget

This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.

Clinical · Molecular biology

Coexisting driver alterations in non-small cell lung cancer: Prevalence, clonal architecture, and impact on survival and progression

Shah R, Pathak GP, Fris J, et al.

European journal of cancer (Oxford, England

A study involving 5420 non-small cell lung cancer (NSCLC) cases investigated the prevalence and impact of coexisting driver genetic alterations. Coexisting mutations were found in 3.9% of tumors, more frequently in females, with KRAS and PIK3CA being the most common combination. Clonality analysis revealed KRAS and EGFR as initiating drivers, while PIK3CA, AKT1, and IDH1 were mostly secondary events. The presence of EGFR + KRAS mutations was significantly associated with worse overall survival in both early and advanced stages. These findings emphasize the importance of comprehensive genomic profiling for effective therapeutic management.

Clinical · Molecular biology

The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation

Jiang L, Luo Y, Liang H, et al.

Human cell

This study investigated the dynamics of circulating tumor cells (CTCs) in 18 patients with advanced KRASG12C-mutated solid tumors treated with glecirasib, a KRASG12C inhibitor. Researchers observed an evolution in CTC subtypes (epithelial, mesenchymal, mixed) during treatment, particularly an increase in mixed CTCs at progression. Baseline CTC levels and their changes correlated with progression-free survival and overall survival. Furthermore, adding local radiotherapy for progressive lesions in patients with more than one CTC at progression significantly prolonged survival.

Clinical

Reversal of KRAS G12D inhibitor resistance by nimotuzumab via MEK/ERK-mediated unfolded protein response in pancreatic cancer

Xue S, Xu H, Ma J, et al.

Cancer letters

This study investigates resistance mechanisms to KRAS G12D inhibitors, such as HRS-4642, in pancreatic ductal adenocarcinoma (PDAC). Researchers identified the reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key mechanism of acquired resistance, observed in vitro, in vivo, and in patients. To overcome this resistance, a combination therapy with nimotuzumab was tested, demonstrating strong synergy and resistance reversal. Nimotuzumab sustained the suppression of the MEK/ERK/UPR axis while exacerbating endoplasmic reticulum stress, leading to profound cellular damage. These findings suggest a promising combined strategy for PDAC patients harboring KRAS G12D mutations.

Clinical · Molecular biology

Lung adenocarcinoma with malignant serous effusions: A comprehensive clinicopathologic, molecular, and outcome analysis

Ma W, Li J, Ould Ismail AA, et al.

Cancer cytopathology

This retrospective study analyzed 120 cases of lung adenocarcinoma (LUAD) with malignant serous effusions (MSE) to characterize their clinicopathologic, molecular, and prognostic features. Pleural effusions were most common, but pericardial involvement was associated with the shortest overall survival. Molecular profiling revealed TP53 mutations and actionable alterations in genes such as EGFR, KRAS, BRAF, ALK, and ROS1. NKX2-1 (TTF-1) negativity and the absence of actionable alterations were independent adverse prognostic factors, with dual NKX2-1/CD274 (PD-L1) negativity defining the poorest prognosis subgroup. Immunotherapy-based regimens and tyrosine kinase inhibitors showed varying survival benefits.

Clinical · Molecular biology

Genetic mutations in metastatic adenocarcinoma of unknown primary

Nagano H, Kiyama S, Kyutoku T, et al.

Otolaryngologia polska = The Polish otolaryngology

This study analyzed the genomic profile of 480 patients with metastatic adenocarcinoma of unknown primary (ACUP) using the FoundationOne CDx platform. The most frequent mutations included TP53, KRAS, and CDKN2A. Results showed that GNAS and PIK3CA mutations were associated with better overall survival. Conversely, ARID1A and NOTCH1 alterations were linked to a worse prognosis. These findings highlight the significance of specific genomic alterations as prognostic markers in ACUP.

Clinical · Molecular biology

Gastric-Type Adenomas of the Nonampullary Duodenum: Reappraisal of Clinicopathological and Molecular Features and a Proposal for Novel Classification

Yamamoto H, Kawatoko S, Oshiro Y, et al.

The American journal of surgical pathology

This study re-evaluates the clinicopathological and molecular features of nonampullary duodenal neoplasms with gastric phenotype, proposing a novel classification. Analyzing 105 lesions, researchers observed a predominance of low-grade tumors and frequent heterogeneity. Next-generation sequencing revealed recurrent mutations in GNAS, KRAS, and APC. MDM2 gene amplification was identified as a potential marker for histological progression in high-grade tumors. Despite morphological diversity, the prognosis was extremely favorable, with no metastases, supporting the reclassification as "gastric-type adenomas."

Clinical · Molecular biology

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy

Oh CR, Lee JY, Kim JE, et al.

Clinical & translational oncology

This prospective observational study assessed the utility of circulating tumor DNA (ctDNA) for mutational profiling and dynamic monitoring in 33 patients with metastatic colorectal cancer receiving palliative chemotherapy. ctDNA was detected in most patients at baseline, revealing frequent mutations in APC, TP53, KRAS, and PIK3CA. Good concordance was observed between plasma ctDNA profiles and tissue data. Longitudinal analysis showed the emergence of acquired mutations, particularly RAS mutations under anti-EGFR therapy, and correlated high ctDNA levels with shorter overall survival. These findings highlight ctDNA’s potential to guide personalized treatment strategies and monitor resistance.